Menu

Sweden Cancels Agreement With Elsevier Over Open Access

A consortium of institutions will not renew its contract with the publisher that ends in June, following the lead of organizations in other countries.

May 16, 2018
Ashley Yeager

WIKIMEDIA, MARCUS HANSSONA collection of Swedish universities and research institutions will not renew its current contract with Elsevier that expires at the end of June, Times Higher Education reports today (May 16). The move comes not long after academic institutions in other countries have let publishers’ subscriptions lapse when fee negotiations come to an impasse.

See “French Universities Cancel Subscriptions to Springer Journals

“The current system for scholarly communication must change, and our only option is to cancel deals when they don’t meet our demands for a sustainable transition to open access,” Astrid Söderbergh Widding, president of Stockholm University and chair of the consortium, tells OpenAccess.se, a blog published by the National Library of Sweden.

According to the blog, the Bibsam Consortium, representing 85 higher education and research institutions in the country, had requested that Elsevier allow researchers at the institutions to publish their work in open access formats and receive reading access to all of the publisher’s journal articles. The consortium also wanted the publisher to commit to a pricing structure that would encourage the move to open access.

In 2017, the consortium’s members spent €12 million ($14.2 million USD) on licensing fees for researchers to read Elsevier content and another €1.3 million ($1.5 million USD) was spent on article-processing charges, OpenAccess.se reports, noting that Swedish researchers publish around 4,000 articles per year in Elsevier journals.

After the contract ends next month, researchers will have access to articles published between 1995 and 2017 but nothing published after June 30, 2018. The consortium has advised researchers interested in studies published after the contract termination date to “search for open-access versions of papers, to contact authors directly for a copy, or to consider an inter-library loan,” according to Times Higher Education.

Other countries, however, have been more successful in creating open-access agreements. Most recently, the Netherlands created subscriptions that combine publishing and reading access into a single fee.

See “Dutch Universities, Journal Publishers Agree on Open-Access Deals

 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.